5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.
Market research firm EvaluatePharma recently released its report looking at the state of the biopharmaceutical industry five years from now. One key area the firm researched was the potential value creation from pipeline products between now and 2022. Here's why Roche (NASDAQOTH: RHHBY), AstraZeneca (NYSE: AZN), AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) ranked at the top.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€141.42
0.770%
With 32 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 196 € shows a positive potential of 38.59% compared to the current price of 141.42 € for Johnson & Johnson.
